Guiding Biotechs From Preclinical to First-in-Human
Our ClinicReady program prepares biotechs for a smooth transition from preclinical to clinical development. Scientific and regulatory specialists help align your preclinical data package, IND-enabling studies, and regulatory strategy, so the first-in-human study is positioned for success.
Early Phase Trials That De-Risks Downstream Development
Avance Clinical is recognized globally for early-phase capabilities built on precision, scientific depth, and operational excellence. With more than 30 years of experience in early phase, hundreds of early-phase studies, and more than 250 therapeutic indications, our teams help biotechs design adaptive protocols, optimize timelines, and generate quality data that de-risks the phases that follow.
Faster, Smarter Early Trials with the Australian Advantage
Australia lets biotechs start most early-phase trials without an IND, with study start-up in 5–6 weeks from final protocol to approval and R&D rebates of up to 43.5% on eligible spend. Avance Clinical’s established operations in Australia and New Zealand help biotechs launch clinical trials faster, generate FDA-accepted data, and maximize their investment before expanding globally.
A Seamless Transition to Global Late-Phase Trials
Through the GlobalReady program, Avance Clinical guides biotechs as they expand from early-phase trials in Australia into late-phase studies in the United States, Asia, the U.K., and Europe. This integrated approach is designed to maintain continuity in data integrity, operational quality, and scientific oversight, minimizing handoff risk and supporting faster time-to-market.
Specialist Knowledge in CNS, Renal & Cardiometabolic, and Oncology
Avance Clinical’s global late-phase team brings deep expertise across complex therapeutic areas: Central Nervous System (CNS), Renal & Cardiometabolic, and Oncology as well as 250 therapeutic indications.
